ArticlePharmaceuticals (Basel, Switzerland)2021

Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy.

Jianling Bi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.